#United States #New York #Securities Fraud #Pomerantz LLP #ADMA Biologics

Pomerantz Law Firm Initiates Investigation into ADMA Biologics

Pomerantz LLP, a prominent name in class-action litigation, has announced its investigation concerning potential claims of securities fraud on behalf of investors in ADMA Biologics, Inc. (NASDAQ: ADMA). The firm is reaching out to investors who may have suffered losses due to recent developments involving the company. The investigation has arisen from allegations of misleading financial reporting and business practices which, if proven true, could have serious legal implications.

Background of ADMA Biologics

ADMA Biologics is a biopharmaceutical company that develops and commercializes specialized immunoglobulin products intended to treat patients with immune deficiencies. While the company has portrayed positive growth patterns, recent scrutiny is challenging those assertions. The focus of the investigation is to determine if ADMA, alongside certain officers and directors, has engaged in unlawful activities that break securities laws, potentially misleading investors about the company's performance and business practices.

The Culper Report's Impact

On March 24, 2026, Culper Research published a damning short report claiming that ADMA's reported growth figures are misleading and result from a deceptive practice often described as 'channel stuffing.' This technique involves inflating sales figures by shipping excess product to distributors, who may or may not be able to sell those products. Culper's report offered a stark contrast, estimating that ADMA’s actual revenues had declined by 3% in 2025, significantly lower than the reported 20% increase.

Following this report, ADMA's stock plummeted by $2.26 per share, translating to a drop of 16.6%, closing at $11.33 on the day of the report's release. The swift market reaction illustrated the investor community's sensitivity to these allegations, emphasizing the urgent need for clarity and transparency from ADMA management.

Downgrades and Further Concerns

Two days later, on March 26, 2026, Cantor Fitzgerald downgraded ADMA's stock rating, expressing disappointment over the company's inadequate response to the allegations raised in the Culper report. Their lack of a detailed rebuttal left many investors feeling uncertain about the firm's governance and business integrity. After this downgrade, ADMA’s stock faced another setback, falling by an additional $1.34 per share (approximately 13.91%).

In a further twist, on May 6, 2026, ADMA Biologics announced the withdrawal of its long-term financial guidance. Leadership cited changing dynamics within the U.S. plasma products and immunoglobulins market as a reason for this shift, raising additional red flags for investors concerned about the company’s future prospects. As a result, the stock price declined again, closing at $8.47 after dropping $1.61—a decline of nearly 16%—the following day.

The Role of Pomerantz LLP

Pomerantz LLP has established itself as a leader in advocating for shareholders' rights, particularly in cases involving securities fraud and corporate misconduct. With a legacy of over 85 years, the firm is recognized for its robust approach to class-action litigation. Pomerantz has successfully recovered substantial damages for investors in numerous cases, providing a glimmer of hope for the investors affected by ADMA's potential malfeasance.

Their investigation will likely encompass a thorough examination of ADMA’s financial reporting practices, internal communications, and contextual factors leading up to the substantial drops in stock price. Investors who believe they have been affected are encouraged to reach out to Pomerantz LLP for assistance.

Conclusion

As the investigation unfolds, shareholders and potential investors are urged to stay informed. The allegations surrounding ADMA Biologics have significant implications for the company’s credibility and market standing. Those who have experienced losses due to the recent price drops should evaluate their options, and consider the potential for legal recourse through Pomerantz LLP. For inquiries, affected investors can contact Danielle Peyton at Pomerantz at [email protected] or call 646-581-9980, ext. 7980.

Given the perpetual evolution of the securities and healthcare markets, the unfolding situation at ADMA Biologics is one to watch closely as investors seek clarity and assurance regarding their investments.